Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Clopidogrel BGR (previously Zylagren)“
Suchtreffer
Begriffe & Kennungen
Clopidogrel BGR (previously Zylagren) · 4.5 · Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomepr
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Other concomitant therapy: Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other co
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Proton Pump Inhibitors (PPI): Omeprazole 80 mg once daily administered either at the same time as clopidogrel
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administratio
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. Ant
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers or antacids in
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thro
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 Undesirable effects · 1
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · 10 Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the m
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · 7 In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass g
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · 8 Immune system Serum sickness, disorders anaphylactoid reactions cross-reactive drug hypersensitivity among t
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · 9 Gastrointestinal Gastrointestinal Gastric ulcer and Retroperitoneal Gastrointestinal and disorders haemorrha
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA g
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.8 · In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus A
Eintrag öffnen